Viridian Therapeutics/$VRDN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Ticker
$VRDN
Sector
Primary listing
Employees
143
Headquarters
Website
VRDN Metrics
BasicAdvanced
$1.5B
-
-$3.56
0.48
-
Price and volume
Market cap
$1.5B
Beta
0.48
52-week high
$25.21
52-week low
$9.90
Average daily volume
767K
Financial strength
Current ratio
11.006
Quick ratio
10.713
Long term debt to equity
2.736
Total debt to equity
4.48
Interest coverage (TTM)
-125.45%
Profitability
EBITDA (TTM)
-371.102
Gross margin (TTM)
-99,761.97%
Net profit margin (TTM)
-112,806.89%
Operating margin (TTM)
-121,831.15%
Management effectiveness
Return on assets (TTM)
-39.77%
Return on equity (TTM)
-65.88%
Valuation
Price to revenue (TTM)
4,572.444
Price to book
4.51
Price to tangible book (TTM)
4.51
Price to free cash flow (TTM)
-4.504
Free cash flow yield (TTM)
-22.20%
Free cash flow per share (TTM)
-4.001
Growth
Revenue change (TTM)
5.90%
Earnings per share change (TTM)
41.77%
3-year revenue growth (CAGR)
-30.13%
3-year earnings per share growth (CAGR)
-7.54%
What the Analysts think about VRDN
Analyst ratings (Buy, Hold, Sell) for Viridian Therapeutics stock.
VRDN Financial Performance
Revenues and expenses
VRDN Earnings Performance
Company profitability
VRDN News
AllArticlesVideos
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results
Benzinga·2 weeks ago
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
Business Wire·2 weeks ago
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viridian Therapeutics stock?
Viridian Therapeutics (VRDN) has a market cap of $1.5B as of August 22, 2025.
What is the P/E ratio for Viridian Therapeutics stock?
The price to earnings (P/E) ratio for Viridian Therapeutics (VRDN) stock is 0 as of August 22, 2025.
Does Viridian Therapeutics stock pay dividends?
No, Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next Viridian Therapeutics dividend payment date?
Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders.
What is the beta indicator for Viridian Therapeutics?
Viridian Therapeutics (VRDN) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.